Health
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer – Medical Xpress
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung…
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas MD Anderson Cancer Center published the study results today in Nature Medicine.
The NEOSTAR…
-
General16 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
General17 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
General18 hours agoAlbanese beats drum on economy as trade clouds gather
-
Noosa News18 hours agoSurgeon partner of former premier to testify over his patient’s death